-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medicine Network November 3rd, November 2nd, the official website of the State Drug Administration shows that China Resources Shuanghe Pharmaceuticals' pivastatin calcium tablets through generic drug consistency evaluation.
2019, sales of pivastatin at public medical institutions in China exceeded 1.5 billion yuan, up 47.50 percent year-on-year, according to the company's internal data.
pyvastatins, used to treat hypercholesterolemia and familial hypercholesterolemia, are third-generation statins, have lower effective doses than other marketed statins, and have the characteristics of the drug metabolase P450 (CYP) metabolism (CYP2C9 has very little metabolism) that is barely liver-free, reducing possible drug interactions. according to
meters of intranet data, in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal pivastatin sales exceeded 1.5 billion yuan, an increase of 47.50 percent year-on-year.
, China Resources Shuanghe accounted for 43.56 percent of the market share, Wanbang Pharmaceuticals accounted for 20.75 percent, Beijing-New Pharmaceuticals accounted for 16.06 percent.
2019 China's public medical institutions terminal Pivastatin brand pattern Source: Minet China's public medical institutions terminal competition pattern of the current domestic market Pivastatin products have pivastatin calcium tablets, pivastatin calcium dispersion tablets.
pivastatin calcium tablets manufacturers have Japan Xinghe, Xinlitai, Qidu Pharmaceuticals, China Resources Shuanghe, Changao Pharmaceuticals, Wanbang Pharmaceuticals and other 5;
pyvastatin for the third batch of harvested varieties.
previously, Xinlitai, Changao Pharmaceuticals, Wanbang Pharmaceuticals of pivastatin calcium tablets have been evaluated and successfully collected, China Resources double crane for the species of the fourth over-evaluation enterprises.
source: MiNet Database, NMPA
